Try our Advanced Search for more refined results

In Re: Actos End Payor

  1. February 16, 2017

    2nd Circ. Actos Ruling Boosts Pharma Antitrust Plaintiffs

    The Second Circuit has revived claims by purchasers of diabetes drug Actos accusing Takeda of delaying generic competition for the drug, providing guidance on antitrust causation in a ruling that smooths over a potential roadblock for plaintiffs in similar suits against pharmaceutical companies.

  2. February 08, 2017

    2nd Circ. Revives Actos Antitrust Suit But Limits Scope

    The Second Circuit on Wednesday revived a proposed class action by purchasers of diabetes drug Actos accusing Takeda of delaying generic competition for the drug, saying they could pursue allegations that Takeda delayed Teva's market entry but not that of other generics makers.

  3. September 16, 2016

    2nd Circ. On Hunt For Antitrust Theory In $2B Takeda Action

    The fate of an antitrust action claiming spurious Takeda Pharmaceutical Co. patent claims cost diabetes patients $2 billion by delaying generic versions of Actos appeared to rest Friday on the Second Circuit's ability to read a cogent theory of anticompetitive conduct into a long 2014 complaint that was not amended after the drugmaker's dismissal motion.

  4. September 15, 2016

    2nd Circ. To Scrutinize Antitrust Causation In Actos Case

    The Second Circuit will hear oral arguments Friday in a bid by purchasers of diabetes drug Actos to revive a class action accusing Takeda of delaying generic competition through fraudulent patent descriptions, a case that will test the hurdles that must be cleared to show harm in antitrust lawsuits.

  5. September 14, 2016

    Takeda Says 2nd Circ. Zanaflex Ruling Torpedoes Actos Row

    Takeda told the Second Circuit on Tuesday that the panel's May ruling in a dispute over multiple sclerosis drug Zanaflex undermines a bid by buyers of the diabetes drug Actos to revive their case accusing Takeda of delaying generic competition for the drug through false patent descriptions.

  6. June 13, 2016

    Actos Direct Buyers Say Drug Mix Patent Can't Block Generic

    Direct buyers of the diabetes drug Actos on Friday asked to file an amicus brief in the Second Circuit appeal of an antitrust suit against Takeda, saying it should not be overlooked that patents for drug combinations can't block a generic version of one of the drugs.

  7. June 06, 2016

    Actos Buyers Cite 2nd Circ. Libor Case In Antitrust Appeal

    Purchasers of the diabetes drug Actos told the Second Circuit on Friday that the court's recent antitrust decision on London Interbank Offered Rate manipulation supports their position that they can sue Takeda over delayed generic competition even if innocent behavior plausibly could have caused the same delay.

  8. May 06, 2016

    Takeda Says 2nd Circ. Shouldn't Revive Actos Antitrust Row

    Takeda urged the Second Circuit on Thursday to affirm the dismissal of antitrust claims over alleged delays in generic competition for the diabetes drug Actos, saying the district court correctly demanded that the buyers show their alleged injury was caused by Takeda's conduct.

  9. March 22, 2016

    Actos Buyers Drop Generic Cos. From Pay-For-Delay Appeal

    Actos diabetes drug buyers who urged the Second Circuit last month to reverse a lower court ruling dismissing their pay-for-delay suit against Takeda and generic-drug makers for not plausibly showing the companies' actions delayed generic Actos from hitting the market agreed Monday to dismiss the generic manufacturers from the appeal.

  10. February 05, 2016

    2nd Circ. Urged To Revive Actos Pay For Delay Row

    Actos diabetes drug buyers told the Second Circuit on Thursday that a lower court wrongly dismissed their pay-for-delay suit against Takeda and five generics makers for not plausibly showing the companies' actions delayed generic Actos from hitting the market.